Newron banks $25.5m before Xadago's FDA go/no-go
This article was originally published in Scrip
With its stock riding close to a seven-year high, and well ahead of an FDA decision on its partnered Parkinson's disease drug, Xadago (safinamide), CNS specialist Newron has raised $25.5m gross from an international group of institutional investors. That gives the Milan-based company around $23-24m to put into its unpartnered earlier-stage pipeline, assuming placing discounts of 5-8%.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.